In the Race for Alternative MOA Biologic in Crohn’s Disease, Takeda’s Entyvio Maintains the Lead, but Janssen’s Stelara is Gaining Fast
Not only has Stelara’s user-base substantially increased since Q1, but US gastroenterologists (n=103) are projecting significant gains for the IL-12/23 inhibitor over the next six months.
EXTON, Pa., June 27, 2017 /PRNewswire/ — Spherix Global Insights has just released the second quarter results of an independent survey regarding the evolving practice patterns in the management of Crohn’s disease (CD). Study findings reveal that despite only minor shifts in biologic brand share over the past quarter, Stelara is poised for significant future growth in the second half of 2017, ultimately encroaching on Entyvio’s share. Indeed, nearly 60% of surveyed gastroenterologists are current Stelara users, a figure anticipated to increase to 77% in the next six months.
Nearly 60% of gastroenterologists project increases in their use of Stelara over the next six months, driving brand share to new highs. While the growth of Stelara will erode share for the leading TNF inhibitors, AbbVie’s Humira and Janssen’s Remicade, overall, use of Entyvio is ultimately anticipated to plateau. Indeed, only one-quarter of gastroenterologists anticipate increasing their use of Entyvio by the end of the year. Furthermore, among those projecting an increase in Stelara use, 70% also report that their use of Entyvio will either decrease or remain unchanged.
These findings are consistent with the results of RealWorld Dynamix™: Biologic Switching in IBD, a large scale syndicated chart analysis of over 1,000 biologic treated patients that recently switched brands. The study revealed that Stelara outpaced Entyvio in the recent CD switch segment. Furthermore, among those patients switched to Stelara, a substantial proportion would have been placed on Entyvio had Stelara not been available.
Despite a potential leveling of the alternate MOA playing field in the future, insurance coverage and the managed care approval process are still barriers for Stelara; when placed in a head to head comparison, Entyvio is favored four to one with regard to insurance coverage. However, Janssen’s newest CD player has a clear perceived advantage over Entyvio with regard to efficacy and ease of administration.
Overall, gastroenterologists report that more than a third of biologic-treated CD patients are not achieving optimal results, leaving a large slice of the market up for grabs. While Entyvio and Stelara are hoping to eat up some of the available pie, new agents in the pipeline have a real opportunity. Agents with an oral formulation are highly desirable in the IBD market, a niche that could potentially be filled by Celgene’s mongersen and ozanimod, as well as JAK inhibitors, including Pfizer’s Xeljanz, AbbVie’s upadacitinib, and Galapagos/Gilead’s filgotinib
The next wave of this study, RealTime Dynamix™, will field in July with a unique sample of gastroenterologists
All company, brand or product names in this document are trademarks of their respective holders.
To view media coverage of this release, click here.
About Spherix Global Insights
Spherix Global Insights is a business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.
For more information contact:
Lynn Price, Immunology Franchise Head